CJC-1295 (with DAC) (CJC-DAC)

CJC-1295 with Drug Affinity Complex that extends half-life dramatically, providing sustained GH elevation over days rather than hours.

Key Data

Research Status

Clinical trials

Half-Life

6-8 days

Administration

Subcutaneous injection

Typical Dosage

1-2 mg per week

Mechanism of Action

GHRH analog with DAC modification allowing albumin binding, creating depot effect for prolonged GH release.

Reported Benefits

• Sustained GH elevation
• Weekly dosing convenience
• Improved body composition
• Enhanced recovery

All information is presented for Research Use Only (RUO). Not medical advice.